ERBB2 and breast cancer: Although most anti-HER2 targeted therapy exerts their action on HER2 protein and no response is observed in IHC scores 0 or 1 + BC patients, there is high concordance between IHC and HER2 gene copy number [45] and no response is observed in ISH-negative cases.